Tenax Therapeutics Names Healey as CCO to Drive TNX-103 Launch
Tenax Therapeutics appointed Timothy Healey, MBA, effective immediately, as Chief Commercial Officer to lead global commercial strategy and prepare TNX-103 for launch. Healey brings leadership experience from Eversana, Lantheus, AbbVie and AMAG, including award-winning drug launches and global commercial oversight.
1. Executive Appointment
Tenax Therapeutics has appointed Timothy Healey, MBA, as Chief Commercial Officer effective immediately, tasking him with shaping the global commercial strategy and launch planning for TNX-103.
2. Extensive Commercial Experience
Healey joins from Eversana Life Science Services, where he led commercial efforts for multiple biopharmaceutical launches, and previously held senior commercial roles at Lantheus, AbbVie and AMAG, earning industry honors such as Brandweek’s Marketer of the Year.
3. Strategic Responsibilities
In his new role, Healey will develop the processes, capabilities and support structures needed to ensure successful market entry of TNX-103, leveraging his track record of translating complex science into commercially successful products.
4. Pipeline and Market Opportunity
Tenax is advancing levosimendan for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension without approved therapies, positioning TNX-103 as a potential first-to-market treatment.